source
- AstraZeneca's Etcamah fails late-stage trial for early-stage breast cancer useAstraZeneca announced that its newly approved breast cancer therapy, Etcamah, did not meet its primary goals in a pivotal study aimed at expanding the drug's label. The trial evaluated Etcamah in…
- Definium’s LSD therapy cuts anxiety scores in second late-stage trialDefinium Therapeutics reported that its LSD-based drug DT120 reduced anxiety symptoms in a second late-stage study. In the 12-week trial, patients receiving a 100-microgram dose saw an average 9.8…